Rep. Julie Johnson Sells Off Shares of Danaher Co. (NYSE:DHR)

Representative Julie Johnson (D-Texas) recently sold shares of Danaher Co. (NYSE:DHR). In a filing disclosed on February 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Danaher stock on January 15th. The trade occurred in the Representative’s “MERRILL LYNCH TAX EFFICIENT CORE” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Dell Technologies (NYSE:DELL) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of ALLETE (NYSE:ALE) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of PPG Industries (NYSE:PPG) on 1/27/2025.
• Purchased $1,001 – $15,000 in shares of Progressive (NYSE:PGR) on 1/24/2025.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 1/24/2025.
• Sold $1,001 – $15,000 in shares of Chubb (NYSE:CB) on 1/24/2025.
• Sold $1,001 – $15,000 in shares of Morgan Stanley (NYSE:MS) on 1/24/2025.
• Purchased $1,001 – $15,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 1/17/2025.

Danaher Stock Up 1.5 %

Danaher stock traded up $2.99 during trading on Friday, hitting $206.58. 1,590,003 shares of the company were exchanged, compared to its average volume of 4,367,576. The company has a market capitalization of $149.21 billion, a P/E ratio of 39.15, a PEG ratio of 2.68 and a beta of 0.83. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The business’s 50 day moving average is $230.00 and its 200 day moving average is $249.96. Danaher Co. has a 52 week low of $196.80 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the previous year, the business posted $2.09 EPS. Analysts predict that Danaher Co. will post 7.67 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were issued a dividend of $0.27 per share. The ex-dividend date was Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.52%. Danaher’s dividend payout ratio (DPR) is currently 20.45%.

Wall Street Analysts Forecast Growth

DHR has been the topic of several recent analyst reports. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a report on Thursday, October 31st. Raymond James reaffirmed a “market perform” rating on shares of Danaher in a report on Monday, February 3rd. Stifel Nicolaus raised their price target on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a report on Wednesday, October 23rd. Barclays reduced their price objective on Danaher from $275.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Finally, Stephens reiterated an “overweight” rating and set a $315.00 price objective on shares of Danaher in a research report on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $278.00.

Hedge Funds Weigh In On Danaher

Several large investors have recently made changes to their positions in the business. Heck Capital Advisors LLC purchased a new stake in shares of Danaher in the fourth quarter worth about $27,000. Decker Retirement Planning Inc. purchased a new stake in shares of Danaher in the fourth quarter worth about $31,000. Golden State Wealth Management LLC purchased a new stake in shares of Danaher in the fourth quarter worth about $31,000. Strategic Financial Concepts LLC purchased a new stake in shares of Danaher in the fourth quarter worth about $31,000. Finally, Pineridge Advisors LLC lifted its position in shares of Danaher by 63.3% in the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock worth $34,000 after buying an additional 57 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. 11.10% of the stock is owned by company insiders.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.